Valeo Pharma Inc.
VPHIF
$0.0469
-$0.0471-50.11%
| Weiss Ratings | VPHIF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Very Weak | |||
| Risk Index | Weak | |||
| Risk Grade | D | |||
| Reward Grade | E | |||
| Rating Factors | VPHIF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Fair | |||
| Efficiency Index | Very Weak | |||
| Solvency Index | Weak | |||
| Total Return Index | Very Weak | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | VPHIF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 2.88 | |||
| Price History | VPHIF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | 0.00% | |||
| 30-Day Total Return | 0.00% | |||
| 60-Day Total Return | 0.00% | |||
| 90-Day Total Return | 0.00% | |||
| Year to Date Total Return | 0.00% | |||
| 1-Year Total Return | -65.21% | |||
| 2-Year Total Return | -87.49% | |||
| 3-Year Total Return | -90.87% | |||
| 5-Year Total Return | -- | |||
| 52-Week High % Change | -60.29% | |||
| 52-Week Low % Change | 36.66% | |||
| Price | VPHIF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $0.12 | |||
| 52-Week Low Price | $0.03 | |||
| 52-Week Low Price (Date) | May 01, 2024 | |||
| 52-Week High Price (Date) | Jun 13, 2024 | |||
| Valuation | VPHIF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 4.63M | |||
| Enterprise Value | 50.67M | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -0.25 | |||
| Earnings Per Share Growth | -0.08% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | 0.12 | |||
| Price/Book (Q) | -0.10 | |||
| Enterprise Value/Revenue (TTM) | 1.25 | |||
| Price | $0.05 | |||
| Enterprise Value/EBITDA (TTM) | -5.23 | |||
| Enterprise Value/EBIT | -4.41 | |||
| Market Cap Category | Nano Cap | |||
| Dividends and Shares | VPHIF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 98.68M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | VPHIF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 514-694-0150 | |||
| Address | 16667 Hymus Boulevard Kirkland, QC H9H 4R9 | |||
| Website | www.valeopharma.com | |||
| Country | Canada | |||
| Year Founded | 2003 | |||
| Profitability | VPHIF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -28.42% | |||
| Profit Margin | -60.15% | |||
| Management Effectiveness | VPHIF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -24.10% | |||
| Return on Equity | -- | |||
| Income Statement | VPHIF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | 39.30M | |||
| Total Revenue (TTM) | 39.30M | |||
| Revenue Per Share | $0.40 | |||
| Gross Profit (TTM) | 7.89M | |||
| EBITDA (TTM) | -9.41M | |||
| EBIT (TTM) | -11.17M | |||
| Net Income (TTM) | -23.64M | |||
| Net Income Avl. to Common (TTM) | -23.64M | |||
| Total Revenue Growth (Q YOY) | -12.82% | |||
| Earnings Growth (Q YOY) | -36.71% | |||
| EPS Diluted (TTM) | -0.25 | |||
| EPS Diluted Growth (Q YOY) | -16.99% | |||
| Balance Sheet | VPHIF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 5.16M | |||
| Cash Per Share (Q) | $0.05 | |||
| Total Current Assets (Q) | 13.80M | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | -45.63M | |||
| Current Ratio (Q) | 0.273 | |||
| Book Value Per Share (Q) | -$0.46 | |||
| Total Assets (Q) | 23.31M | |||
| Total Current Liabilities (Q) | 50.61M | |||
| Total Debt (Q) | 51.20M | |||
| Total Liabilities (Q) | 68.94M | |||
| Total Common Equity (Q) | -45.63M | |||
| Cash Flow | VPHIF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | -2.59M | |||
| Cash from Financing (TTM) | 3.26M | |||
| Net Change in Cash (TTM) | -1.95M | |||
| Levered Free Cash Flow (TTM) | -3.24M | |||
| Cash from Operations (TTM) | -2.87M | |||
